More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs.
As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback